$55.62
2.06% yesterday
Nasdaq, Jul 14, 10:00 pm CET
ISIN
NL0011606264
Symbol
MRUS
Sector
Industry

Merus N.V. Stock price

$55.62
+2.32 4.35% 1M
+16.62 42.60% 6M
+13.57 32.27% YTD
-2.48 4.27% 1Y
+28.17 102.62% 3Y
+41.48 293.35% 5Y
+45.58 453.98% 10Y
+45.58 453.98% 20Y
Nasdaq, Closing price Mon, Jul 14 2025
+1.12 2.06%
ISIN
NL0011606264
Symbol
MRUS
Sector
Industry

Key metrics

Basic
Market capitalization
$4.1b
Enterprise Value
$3.6b
Net debt
positive
Cash
$458.3m
Shares outstanding
69.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
74.2 | 66.8
EV/Sales
65.8 | 59.3
EV/FCF
negative
P/B
6.8
Financial Health
Equity Ratio
82.8%
Return on Equity
-33.2%
ROCE
-46.9%
ROIC
-136.4%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$54.7m | $60.7m
EBITDA
$-298.6m | $-313.1m
EBIT
$-301.0m | $-340.0m
Net Income
$-277.3m | $-341.6m
Free Cash Flow
$-239.9m
Growth (TTM | estimate)
Revenue
42.8% | 68.1%
EBITDA
-82.0% | -16.1%
EBIT
-80.7% | -25.0%
Net Income
-85.3% | -58.6%
Free Cash Flow
-59.6%
Margin (TTM | estimate)
Gross
-
EBITDA
-545.5% | -515.5%
EBIT
-550.0%
Net
-506.7% | -562.4%
Free Cash Flow
-438.2%
More
EPS
$-4.0
FCF per Share
$-3.5
Short interest
6.7%
Employees
291
Rev per Employee
$120.0k
Show more

Is Merus N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Merus N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Merus N.V. forecast:

23x Buy
96%
1x Hold
4%

Analyst Opinions

24 Analysts have issued a Merus N.V. forecast:

Buy
96%
Hold
4%

Financial data from Merus N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
55 55
43% 43%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 89 89
47% 47%
162%
- Research and Development Expense 267 267
85% 85%
488%
-299 -299
82% 82%
-545%
- Depreciation and Amortization 2.45 2.45
5% 5%
4%
EBIT (Operating Income) EBIT -301 -301
81% 81%
-550%
Net Profit -277 -277
85% 85%
-507%

In millions USD.

Don't miss a Thing! We will send you all news about Merus N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Merus N.V. Stock News

Neutral
GlobeNewsWire
12 days ago
TAMPERE, Finland, July 03, 2025 (GLOBE NEWSWIRE) -- The energy storage facility delivered by Merus Power to Lappeenranta, Finland, has been completed and put into market use on 15 May 2025. The energy storage facility is owned by a joint venture between Ardian's Clean Energy Evergreen Fund and the local energy provider Lappeenrannan Energia. It is one of the largest energy storage facilities in...
Positive
Seeking Alpha
about one month ago
MRUS initially surged on superior interim trial data while BCAX tanked, but BCAX has since rebounded post-ASCO as investors reconsider the data and target market. BCAX targets the tougher HPV-negative head and neck cancer segment, representing 80% of cases, and boasts a higher complete response rate than MRUS. Despite analyst preference for MRUS, BCAX's durability argument and deep response rat...
Neutral
GlobeNewsWire
about one month ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the pricing of an underwritten public offering of 5,263,158 common shares, at a p...
More Merus N.V. News

Company Profile

Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bi-specific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.

Head office Netherlands
CEO Bill Lundberg
Employees 291
Founded 2003
Website merus.nl

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today